Tau PET in Alzheimer disease and mild cognitive impairment

Hanna Cho, Jae Yong Choi, Mi Song Hwang, Jae Hoon Lee, You Jin Kim, Hye Mi Lee, Chulhyoung Lyoo, Young Hoon Ryu, Myung Sik Lee

Research output: Contribution to journalArticle

78 Citations (Scopus)

Abstract

Objective: To investigate the topographical distribution of tau pathology and its effect on functional and structural changes in patients with Alzheimer disease (AD) and mild cognitive impairment (MCI) by using 18 F-AV-1451 PET. Methods: We included 20 patients with AD, 15 patients with MCI, and 20 healthy controls, and performed neuropsychological function tests, MRI, as well as 18 F-florbetaben (for amyloid) and 18 F-AV-1451 (for tau) PET scans. By using the regional volume-of-interest masks extracted from MRIs, regional binding values of standardized uptake value ratios and volumes were measured. We compared regional binding values among 3 diagnostic groups and identified correlations among the regional binding values, performance in each cognitive function test, and regional atrophy. Results: 18 F-AV-1451 binding was increased only in the entorhinal cortex in patients with MCI, while patients with AD exhibited greater binding in most cortical regions. In the 35 patients with MCI and AD, 18 F-AV-1451 binding in most of the neocortex increased with a worsening of global cognitive function. The visual and verbal memory functions were associated with the extent of 18 F-AV-1451 binding, especially in the medial temporal regions. The 18 F-AV-1451 binding also correlated with the severity of regional atrophy of the cerebral cortex. Conclusions: Tau PET imaging with 18 F-AV-1451 could serve as an in vivo biomarker for the evaluation of AD-related tau pathology and monitoring disease progression. The accumulation of pathologic tau is more closely related to functional and structural deterioration in the AD spectrum than β-amyloid.

Original languageEnglish
Pages (from-to)375-383
Number of pages9
JournalNeurology
Volume87
Issue number4
DOIs
Publication statusPublished - 2016 Jul 26

Fingerprint

Alzheimer Disease
Amyloid
Cognition
Atrophy
Pathology
Entorhinal Cortex
Neuropsychological Tests
Neocortex
Temporal Lobe
Masks
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole
Cognitive Dysfunction
Positron-Emission Tomography
Cerebral Cortex
Disease Progression
Biomarkers

All Science Journal Classification (ASJC) codes

  • Clinical Neurology

Cite this

Cho, H., Choi, J. Y., Hwang, M. S., Lee, J. H., Kim, Y. J., Lee, H. M., ... Lee, M. S. (2016). Tau PET in Alzheimer disease and mild cognitive impairment. Neurology, 87(4), 375-383. https://doi.org/10.1212/WNL.0000000000002892
Cho, Hanna ; Choi, Jae Yong ; Hwang, Mi Song ; Lee, Jae Hoon ; Kim, You Jin ; Lee, Hye Mi ; Lyoo, Chulhyoung ; Ryu, Young Hoon ; Lee, Myung Sik. / Tau PET in Alzheimer disease and mild cognitive impairment. In: Neurology. 2016 ; Vol. 87, No. 4. pp. 375-383.
@article{6e73ce4b646d4e6d9a609c740efac634,
title = "Tau PET in Alzheimer disease and mild cognitive impairment",
abstract = "Objective: To investigate the topographical distribution of tau pathology and its effect on functional and structural changes in patients with Alzheimer disease (AD) and mild cognitive impairment (MCI) by using 18 F-AV-1451 PET. Methods: We included 20 patients with AD, 15 patients with MCI, and 20 healthy controls, and performed neuropsychological function tests, MRI, as well as 18 F-florbetaben (for amyloid) and 18 F-AV-1451 (for tau) PET scans. By using the regional volume-of-interest masks extracted from MRIs, regional binding values of standardized uptake value ratios and volumes were measured. We compared regional binding values among 3 diagnostic groups and identified correlations among the regional binding values, performance in each cognitive function test, and regional atrophy. Results: 18 F-AV-1451 binding was increased only in the entorhinal cortex in patients with MCI, while patients with AD exhibited greater binding in most cortical regions. In the 35 patients with MCI and AD, 18 F-AV-1451 binding in most of the neocortex increased with a worsening of global cognitive function. The visual and verbal memory functions were associated with the extent of 18 F-AV-1451 binding, especially in the medial temporal regions. The 18 F-AV-1451 binding also correlated with the severity of regional atrophy of the cerebral cortex. Conclusions: Tau PET imaging with 18 F-AV-1451 could serve as an in vivo biomarker for the evaluation of AD-related tau pathology and monitoring disease progression. The accumulation of pathologic tau is more closely related to functional and structural deterioration in the AD spectrum than β-amyloid.",
author = "Hanna Cho and Choi, {Jae Yong} and Hwang, {Mi Song} and Lee, {Jae Hoon} and Kim, {You Jin} and Lee, {Hye Mi} and Chulhyoung Lyoo and Ryu, {Young Hoon} and Lee, {Myung Sik}",
year = "2016",
month = "7",
day = "26",
doi = "10.1212/WNL.0000000000002892",
language = "English",
volume = "87",
pages = "375--383",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

Cho, H, Choi, JY, Hwang, MS, Lee, JH, Kim, YJ, Lee, HM, Lyoo, C, Ryu, YH & Lee, MS 2016, 'Tau PET in Alzheimer disease and mild cognitive impairment', Neurology, vol. 87, no. 4, pp. 375-383. https://doi.org/10.1212/WNL.0000000000002892

Tau PET in Alzheimer disease and mild cognitive impairment. / Cho, Hanna; Choi, Jae Yong; Hwang, Mi Song; Lee, Jae Hoon; Kim, You Jin; Lee, Hye Mi; Lyoo, Chulhyoung; Ryu, Young Hoon; Lee, Myung Sik.

In: Neurology, Vol. 87, No. 4, 26.07.2016, p. 375-383.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Tau PET in Alzheimer disease and mild cognitive impairment

AU - Cho, Hanna

AU - Choi, Jae Yong

AU - Hwang, Mi Song

AU - Lee, Jae Hoon

AU - Kim, You Jin

AU - Lee, Hye Mi

AU - Lyoo, Chulhyoung

AU - Ryu, Young Hoon

AU - Lee, Myung Sik

PY - 2016/7/26

Y1 - 2016/7/26

N2 - Objective: To investigate the topographical distribution of tau pathology and its effect on functional and structural changes in patients with Alzheimer disease (AD) and mild cognitive impairment (MCI) by using 18 F-AV-1451 PET. Methods: We included 20 patients with AD, 15 patients with MCI, and 20 healthy controls, and performed neuropsychological function tests, MRI, as well as 18 F-florbetaben (for amyloid) and 18 F-AV-1451 (for tau) PET scans. By using the regional volume-of-interest masks extracted from MRIs, regional binding values of standardized uptake value ratios and volumes were measured. We compared regional binding values among 3 diagnostic groups and identified correlations among the regional binding values, performance in each cognitive function test, and regional atrophy. Results: 18 F-AV-1451 binding was increased only in the entorhinal cortex in patients with MCI, while patients with AD exhibited greater binding in most cortical regions. In the 35 patients with MCI and AD, 18 F-AV-1451 binding in most of the neocortex increased with a worsening of global cognitive function. The visual and verbal memory functions were associated with the extent of 18 F-AV-1451 binding, especially in the medial temporal regions. The 18 F-AV-1451 binding also correlated with the severity of regional atrophy of the cerebral cortex. Conclusions: Tau PET imaging with 18 F-AV-1451 could serve as an in vivo biomarker for the evaluation of AD-related tau pathology and monitoring disease progression. The accumulation of pathologic tau is more closely related to functional and structural deterioration in the AD spectrum than β-amyloid.

AB - Objective: To investigate the topographical distribution of tau pathology and its effect on functional and structural changes in patients with Alzheimer disease (AD) and mild cognitive impairment (MCI) by using 18 F-AV-1451 PET. Methods: We included 20 patients with AD, 15 patients with MCI, and 20 healthy controls, and performed neuropsychological function tests, MRI, as well as 18 F-florbetaben (for amyloid) and 18 F-AV-1451 (for tau) PET scans. By using the regional volume-of-interest masks extracted from MRIs, regional binding values of standardized uptake value ratios and volumes were measured. We compared regional binding values among 3 diagnostic groups and identified correlations among the regional binding values, performance in each cognitive function test, and regional atrophy. Results: 18 F-AV-1451 binding was increased only in the entorhinal cortex in patients with MCI, while patients with AD exhibited greater binding in most cortical regions. In the 35 patients with MCI and AD, 18 F-AV-1451 binding in most of the neocortex increased with a worsening of global cognitive function. The visual and verbal memory functions were associated with the extent of 18 F-AV-1451 binding, especially in the medial temporal regions. The 18 F-AV-1451 binding also correlated with the severity of regional atrophy of the cerebral cortex. Conclusions: Tau PET imaging with 18 F-AV-1451 could serve as an in vivo biomarker for the evaluation of AD-related tau pathology and monitoring disease progression. The accumulation of pathologic tau is more closely related to functional and structural deterioration in the AD spectrum than β-amyloid.

UR - http://www.scopus.com/inward/record.url?scp=84980378955&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84980378955&partnerID=8YFLogxK

U2 - 10.1212/WNL.0000000000002892

DO - 10.1212/WNL.0000000000002892

M3 - Article

VL - 87

SP - 375

EP - 383

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 4

ER -

Cho H, Choi JY, Hwang MS, Lee JH, Kim YJ, Lee HM et al. Tau PET in Alzheimer disease and mild cognitive impairment. Neurology. 2016 Jul 26;87(4):375-383. https://doi.org/10.1212/WNL.0000000000002892